Q-Med AB: Invitation to half-year report conference call

Q-Med AB: Invitation to half-year report conference call

Time: Thursday, July 26, 2007 at 11.30 a.m. CET.

To join the conference
Sweden: +46 (0)8 505 201 10
UK: +44 (0)20 7162 0025
Password: Q-Med

Q-Med participants:
Bengt Ågerup, CEO
Erika Kjellberg Eriksson, CFO
Madelene Sandgren, Director IR and Corporate Communications

The press release for Q-Med AB´s half-year report will be issued around 
10.30 a.m. CET July 26.

The slide presentation will be available at
www.q-med.com/Investors/Presentations

A recorded version of the presentation will be available for seven working days
on Sweden: +46 (0)8 505 203 33, UK: +44 (0)20 7031 4064, access code: 759837

Queries should be addressed to: 
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70 974 9015

Q-Med AB is a rapidly growing and profitable biotechnology/medical device
company. The company develops, manufactures, markets and sells primarily medical
implants. The majority of the products are based on the company's patented
technology, NASHA™ for the production of stabilized non-animal hyaluronic acid. 
The product portfolio today contains: RESTYLANE for the filling out of lips and
facial wrinkles and for facial contouring, DUROLANE, for the treatment of
osteoarthritis of the hip and knee joints, DEFLUX for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
ZUIDEX, for the treatment of stress urinary incontinence in women and SOLESTA,
for the treatment of fecal incontinence. Sales are made through the company's
own subsidiaries or distributors in over 70 countries. Q-Med today has just over
600 co-workers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Large Cap
segment of the OMX Nordic Exchange in Stockholm.

NASHA, DUROLANE, SOLESTA, ZUIDEX, IMPLACER, DEFLUX and all product names within
the RESTYLANE family are trademarks that belong to Q-Med AB.